Pathogen recognition and development of particulate vaccines: does size matter?
about
Factoring-in agglomeration of carbon nanotubes and nanofibers for better prediction of their toxicity versus asbestosThe Use of Synthetic Carriers in Malaria Vaccine DesignSynthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial VirusBiodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes TargetingUltrasonic synthetic technique to manufacture a pHEMA nanopolymeric-based vaccine against the H6N2 avian influenza virus: a preliminary investigation.Shape induced inhibition of phagocytosis of polymer particles.Polymeric Materials for Gene Delivery and DNA VaccinationAdvances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonistsDNA-encapsulated magnesium phosphate nanoparticles elicit both humoral and cellular immune responses in mice.TLR 9 activation in dendritic cells enhances salmonella killing and antigen presentation via involvement of the reactive oxygen species.In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants.Using carbon magnetic nanoparticles to target, track, and manipulate dendritic cellsCan carbon spheres be created through the Stöber method?LOS oligosaccharide modification enhances dendritic cell responses to meningococcal native outer membrane vesicles expressing a non-toxic lipid AA polymer/oil based nanovaccine as a single-dose immunization approach.Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner.Antigen-expressing immunostimulatory liposomes as a genetically programmable synthetic vaccineVirus aggregating peptide enhances the cell-mediated response to influenza virus vaccineStructure, size, and solubility of antigen arrays determines efficacy in experimental autoimmune encephalomyelitis.Dendritic Cell-Mediated Phagocytosis but Not Immune Activation Is Enhanced by PlasminStrategies to guide the antibody affinity maturation processA TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanismsRapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity.Antigen presentation kinetics control T cell/dendritic cell interactions and follicular helper T cell generation in vivo.Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responsesType VI secretion system sheaths as nanoparticles for antigen display.A Candida albicans mannoprotein deprived of its mannan moiety is efficiently taken up and processed by human dendritic cells and induces T-cell activation without stimulating proinflammatory cytokine productionCutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3.Single-dose microparticle delivery of a malaria transmission-blocking vaccine elicits a long-lasting functional antibody response.Nanocarrier-based immunotherapy in cancer management and research.Design opportunities for actively targeted nanoparticle vaccines.Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity.Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors.Promising particle-based vaccines in cancer therapy.Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine.Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis.Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccinesRole of particle size in phagocytosis of polymeric microspheresNeisseria lactamica antigens complexed with a novel cationic adjuvant
P2860
Q23910152-DF364209-BC77-4AEA-9A0C-04F15DDBDACDQ26777053-B6A02372-D795-4C96-8377-3412A490D326Q28067143-35E0DB86-CB59-421F-B9EE-F19386F744CAQ28072997-85AD695A-6EA9-4111-957A-9DEBBF5EFDFBQ30409922-767FB2D4-76DB-45C7-965C-E1E8509D89CAQ30492878-157AD1B1-D42D-4DE6-9648-D4A267DD4D2CQ33565296-6F8570D0-FC55-4BEC-9AEE-AC4B85F7B108Q33721641-C75D2A41-1980-4A20-85CD-7D8A26A58318Q33730191-C6F93378-D744-4DA2-8054-2C1B03183ABAQ33737432-79E110FD-9A50-472F-9E3B-34518FA604D7Q33901007-041FE2F9-6869-413F-89CE-6A47FF7D0F78Q34121001-C95BCD6E-5747-44D7-8DA1-7AEB13F6FDE4Q34216537-2DF0CE47-BFE5-4BFA-A898-1FCB23F80FBEQ34376049-BBAECA78-1D6F-4977-89EC-60F23CCFFBC2Q34685874-F190003C-36D0-4528-AC00-1381DF29201CQ35165017-21F5B958-3DD6-4FC0-9273-044E886FFB3CQ35175380-9EFEC269-A087-44D8-A74A-B3311F8F9DBAQ35301495-26248496-6FB0-41CD-8050-3CCF6DD160A0Q35318199-0444F9B6-2E8C-4706-8804-84E586804753Q35680210-3B231DED-DE5F-4110-A462-61C6A69E7856Q35685300-7B5CE87C-E89C-49AD-8D0A-E2F19A014E06Q35895400-839CC505-6A2C-4FE6-9074-BF10C27BCDADQ35983565-11B8EF8C-1031-4C6D-869A-075775C264E9Q36022467-8DAAA70F-443A-46BB-905C-DE9319CA627FQ36126960-1E7A5AD5-593F-4F01-9C2D-E3F7C062ACE1Q36710694-92EAA9FE-1901-4A44-A717-D5D6374F7BF0Q36845263-2C387449-9B32-4CCF-A831-F12DC806CB6FQ36983584-54098C16-EF1F-4853-AF8B-BAAA57E8D667Q36998403-E8CE5A22-8AE5-4FCD-8A70-523882C66EA9Q37031671-5D7BDCD2-E07A-4E4C-80F9-D65EABB60CACQ37062606-ECC48BD6-F2E2-49E4-880C-85955B06C4F6Q37103959-F26102F1-9F97-4A57-8731-FCBE5F6BE409Q37135255-37F52F55-CDFA-408D-8622-B07E4DBECA86Q37259611-9764C9C2-9977-40F0-A6B1-4BCB95FDE11FQ37259642-C10D3571-5BD5-4E5E-8086-A90C37292C31Q37373733-262705FD-6D3F-46E5-B920-8275BBE16C1AQ37378031-8B77DD31-AC45-47BD-A1F9-35A451A197EDQ37401011-E678AFDB-F1C8-4EA6-8C86-9013C7CED08FQ37475631-11BFBE47-12F9-405B-9827-8546144441C2Q37478314-6161FA2A-E461-4809-AC51-5419B3FE1154
P2860
Pathogen recognition and development of particulate vaccines: does size matter?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Pathogen recognition and development of particulate vaccines: does size matter?
@ast
Pathogen recognition and development of particulate vaccines: does size matter?
@en
type
label
Pathogen recognition and development of particulate vaccines: does size matter?
@ast
Pathogen recognition and development of particulate vaccines: does size matter?
@en
prefLabel
Pathogen recognition and development of particulate vaccines: does size matter?
@ast
Pathogen recognition and development of particulate vaccines: does size matter?
@en
P2093
P50
P1433
P1476
Pathogen recognition and development of particulate vaccines: does size matter?
@en
P2093
Cassandra David
Gabriela Minigo
Magdalena Plebanski
Patricia L Mottram
P356
10.1016/J.YMETH.2006.05.016
P577
2006-09-01T00:00:00Z